The Impact of Social Networks on Enhancing Safety and Efficacy Outcomes in Low-Dose Rituximab Treatment for Central Nervous System Demyelinating Diseases

Document Type : Original Article

Authors

1 Assistant Professor and Chief of Neurosurgery Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

2 Assistant Professor of Neurology Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

3 Assistant Professor of Neurosurgery Department, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

4 Department of Neurology, Rasool-e Akram Hospital, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

5 Shefa Neuroscience Research Center, Khatam Al Anbia Hospital, Tehran, Iran

6 Department of Pharmacoeconomics and Pharmaceutical Administration, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

7 The Institute of Pharmaceutical Sciences, Tehran University of Medical Sciences, Tehran, Iran

8 Department of Anatomical Sciences, School of Medicine, Iran university of Medical Sciences, Tehran, Iran

9 Pharmacist, University College London, England, London

10 Medical Student, Iran university of Medical Sciences, Tehran, Iran

Abstract

Background: In the realm of healthcare, the symbiotic relationship between social networks and medical advancements has attracted significant attention. This study aimed to explore the effectiveness and safety of this approach, with a particular focus on the role of social networks in disseminating information and shaping patient experiences.
Methods: In a prospective single-arm interventional study, we examined the effects of integrating social networks – Skype and WhatsApp – to enhance the safety and efficacy outcomes of low-dose Rituximab treatment for CNS Demyelinating Diseases. A total of 99 patients eligible for treatment were recruited, and ethical consent was secured. The intervention involved informative Skype groups, led by medical experts, providing education and follow-up, and WhatsApp groups for peer support and question-answer sessions. Clinical data and interaction metrics were collected to evaluate treatment outcomes and engagement levels.
Results: A total of 99 patients received rituximab, with 42 diagnosed with RRMS, 43 with SPMS, and 14 with Neuromyelitis Optica Spectrum Disorder (NMOSD). The treatment period ranged from 12 to 40 months. Among the Relapsing-remitting Multiple Sclerosis (RRMS) patients, 8 (19%) experienced new attacks, while 10 (23%) of the Secondary-progressive Multiple Sclerosis (SPMS) patients and 1 (7%) of the NMOSD patients had new attacks. In cases of RRMS and NMOSD, there was a decrease in Expanded Disability Status Scale (EDSS) scores. Additionally, SPMS and NMOSD patients showed a decrement in serum IgG levels. Two cases of drug adverse events were reported. Mean EDSS variability had a decrease in RRMS (-0.32, P=0.06) and NMOSD (-0.57, P=0.004) and had a slight increase among patients with SPMS (+0.19, P=0.23).
Conclusion: Recognizing the influence of social networks can enhance patient care and create customized support systems. By combining findings from clinical evaluations with insights gained from social media interactions, we could provide a multifaceted perspective on safety and effectiveness.

Keywords

References

  1. Tsao S-F, Chen H, Tisseverasinghe T, Yang Y, Li L, Butt ZA. What social media told us in the time of COVID-19: a scoping review. The Lancet Digital Health. 2021;3(3):e175-e94. . doi: 10.1016/S2589-7500(20)30315-0. PubMed PMID: 33518503; PubMed Central PMCID: PMC7906737.
  2. Zhuravskaya E, Petrova M, Enikolopov R. Political effects of the internet and social media. Annual review of economics. 2020;12:415-38. doi: 10.1146/annurev-economics-081919-050239.
  3. Olanrewaju A-ST, Hossain MA, Whiteside N, Mercieca P. Social media and entrepreneurship research: A literature review. International Journal of Information Management. 2020;50:90-110. doi: 10.1016/j.ijinfomgt.2019.05.011.
  4. Eizaguirre MB, Ciufia N, Roman MS, Martínez Canyazo C, Alonso R, Silva B, Pita C, Garcea O, Vanotti S. Perceived fatigue in multiple sclerosis: The importance of highlighting its impact on quality of life, social network and cognition. Clin Neurol Neurosurg. 2020;199:106265. doi: 10.1016/j.clineuro.2020.106265. PubMed PMID: 33038658.
  5. Mirmosayyeb O, Ghaffary EM, Vaheb S, Pourkazemi R, Shaygannejad V. Multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccines: A systematic review. Rev Neurol (Paris). 2023;179(4):265-281. doi: 10.1016/j.neurol.2022.11.004. PubMed PMID: 36658048; PubMed Central PMCID: PMC9844421.
  6. Kang J, Kim SY, Vallejo D, Hageman TS, White DR, Benet A, Coghlan J, Sen KI, Ford M, Saveliev S, Tolbert TJ, Weis DD, Schwendeman SP, Ruotolo BT, Schwendeman A. Multifaceted assessment of rituximab biosimilarity: The impact of glycan microheterogeneity on Fc function. Eur J Pharm Biopharm. 2020;146:111-124. doi: 10.1016/j.ejpb.2019.12.003. PubMed PMID: 31841688.
  7. D'Amico E, Zanghì A, Chisari CG, Fermo SL, Toscano S, Arena S, Patti F, Zappia M. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: An Italian experience. Mult Scler Relat Disord. 2019;27:324-326. doi: 10.1016/j.msard.2018.09.041. PubMed PMID: 30471585.
  8. Lavorgna L, Brigo F, Moccia M, Leocani L, Lanzillo R, Clerico M, Abbadessa G, Schmierer K, Solaro C, Prosperini L, Tedeschi G, Giovannoni G, Bonavita S. e-Health and multiple sclerosis: An update. Mult Scler. 2018;24(13):1657-1664. doi: 10.1177/1352458518799629. PubMed PMID: 30231004.
  9. Hernández-Rodríguez J, Carbonell C, Mirón-Canelo JA, Diez-Ruiz S, Marcos M, Chamorro AJ. Rituximab treatment for IgA vasculitis: A systematic review. Autoimmun Rev. 2020;19(4):102490. doi: 10.1016/j.autrev.2020.102490. PubMed PMID: 32062030.
  10. Rostami A, Abbasi Y, Jamalnia S, Asadian A, Enani H, Jafarinia M. Mesenchymal Stem Cells as A New Approach for the Treatment of Multiple Sclerosis:A Literature Review : Galen Med J. 2022;11:e2529. doi: 10.31661/gmj.v11i.2529. PubMed PMID: 37200683; PubMed Central PMCID: PMC10188250.
  11. Ortiz-Ospina E, Roser M. The rise of social media. Our World in Data. 2019. Available from: https://ourworldindata.org/rise-of-social-media.
  12. Auxier B, Anderson M. Social media use in 2021. Pew Research Center. 2021;1:1-4. Available from: https://www.pewresearch.org/internet/2021/04/07/social-media-use-in-2021.
  13. Farsi D. Social Media and Health Care, Part I: Literature Review of Social Media Use by Health Care Providers. J Med Internet Res. 2021;23(4):e23205. doi: 10.2196/23205. PubMed PMID: 33664014; PubMed Central PMCID: PMC8056296.
  14. Zhao D, Zhao C, Lu J, Han Y, Sun T, Ren K, Ma C, Zhang C, Li H, Guo J. Efficacy and safety of repeated low-dose rituximab therapy in relapsing-remitting multiple sclerosis: A retrospective case series study. Mult Scler Relat Disord. 2023;70:104518. doi: 10.1016/j.msard.2023.104518. PubMed PMID: 36657326.
  15. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. doi: 10.1016/S1474-4422(17)30470-2. PubMed PMID: 29275977.
  16. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG; International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177-89. doi: 10.1212/WNL.0000000000001729. PubMed PMID: 26092914; PubMed Central PMCID: PMC4515040.
  17. Lavorgna L, De Stefano M, Sparaco M, Moccia M, Abbadessa G, Montella P, Buonanno D, Esposito S, Clerico M, Cenci C, Trojsi F, Lanzillo R, Rosa L, Morra VB, Ippolito D, Maniscalco G, Bisecco A, Tedeschi G, Bonavita S. Fake news, influencers and health-related professional participation on the Web: A pilot study on a social-network of people with Multiple Sclerosis. Mult Scler Relat Disord. 2018;25:175-178. doi: 10.1016/j.msard.2018.07.046. PubMed PMID: 30096683.
  18. Costa WA, Monteiro MN, Queiroz JF, Gonçalves AK. Pain and quality of life in breast cancer patients. Clinics (Sao Paulo). 2017;72(12):758-763. doi: 10.6061/clinics/2017(12)07. PubMed PMID: 29319722; PubMed Central PMCID: PMC5738557.
  19. Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, Hauser S, Waubant E, Vollmer T, Panitch H, Zhang J, Chin P, Smith CH; OLYMPUS trial group. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol. 2009;66(4):460-71. doi: 10.1002/ana.21867. PubMed PMID: 19847908.
  20. Scotti B, Disanto G, Sacco R, Guigli M, Zecca C, Gobbi C. Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland. PLoS One. 2018;13(5):e0197415. doi: 10.1371/journal.pone.0197415. PubMed PMID: 29758075; PubMed Central PMCID: PMC5951582.
  21. Greenberg BM, Graves D, Remington G, Hardeman P, Mann M, Karandikar N, Stuve O, Monson N, Frohman E. Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler. 2012;18(7):1022-6. doi: 10.1177/1352458511432896. PubMed PMID: 22261118.
  22. Zéphir H, Bernard-Valnet R, Lebrun C, Outteryck O, Audoin B, Bourre B, Pittion S, Wiertlewski S, Ouallet JC, Neau JP, Ciron J, Clavelou P, Marignier R, Brassat D. Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol. 2015;262(10):2329-35. doi: 10.1007/s00415-015-7852-y. PubMed PMID: 26194198.
  23. Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, Maillart E, Papeix C, Vukusic S, Zephir H, Marignier R, Collongues N; NOMADMUS group, under the aegis of OFSEP, SFSEP. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris). 2018;174(4):255-264. doi: 10.1016/j.neurol.2017.11.005. PubMed PMID: 29606320.
  24. Ali M, Bilal HSM, Razzaq MA, Khan J, Lee S, Idris M, et al. IoTFLiP: IoT-based flipped learning platform for medical education. Digit Commun Netw. 2017;3(3):188-94. doi: 10.1016/j.dcan.2017.03.002.
  25. Sakurai R, Kawai H, Suzuki H, Kim H, Watanabe Y, Hirano H, Ihara K, Obuchi S, Fujiwara Y. Poor Social Network, Not Living Alone, Is Associated With Incidence of Adverse Health Outcomes in Older Adults. J Am Med Dir Assoc. 2019;20(11):1438-1443. doi: 10.1016/j.jamda.2019.02.021. PubMed PMID: 31000349.
  26. Ali F, El-Sappagh S, Islam SR, Ali A, Attique M, Imran M, et al. An intelligent healthcare monitoring framework using wearable sensors and social networking data. Future Generation Computer Systems. 2021;114:23-43. doi: 10.1016/j.future.2020.07.047.
  27. Neely S, Eldredge C, Sanders R. Health Information Seeking Behaviors on Social Media During the COVID-19 Pandemic Among American Social Networking Site Users: Survey Study. J Med Internet Res. 2021;23(6):e29802. doi: 10.2196/29802. PubMed PMID: 34043526; PubMed Central PMCID: PMC8202660.
Interdisciplinary Journal of Virtual Learning in Medical Sciences
Volume 14, Issue 3 - Serial Number 54
September 2023
Pages 206-215

Files

History

  • Receive Date: 06 March 2023
  • Revise Date: 21 March 2023
  • Accept Date: 11 April 2023
  • Publish Date: 01 September 2023

Share

How to cite

Statistics